An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy

Keyphrases

• Prostatectomy 100%
• Prostate Cancer Patients 100%
• Progression-free Survival 100%
• Ki-67 100%
• Ki-67 Expression 100%
• Adjuvant Docetaxel 100%
• MYC Expression 75%
• Multivariable 50%
• Primary Tumor 50%
• Prostate-specific Antigen Level 50%
• Protein Markers 50%
• High-grade Prostate Cancer 50%
• Prostate Cancer 25%
• Radiologic 25%
• Prognostic Significance 25%
• Clinical Information 25%
• Prognostic Implications 25%
• Clinical Factors 25%
• Immunohistochemical Analysis 25%
• Proportional Hazards Regression Analysis 25%
• Phosphorylated Forms 25%
• Univariate Analysis 25%
• Tumor Protein p53 (TP53) 25%
• Prostatectomy Specimen 25%
• Tumor Samples 25%
• Independent Prognostic Factor 25%
• Clinical Trial Design 25%
• PTEN Protein 25%
• Protein Loss 25%
• Tumor Suppressor PTEN 25%
• Therapeutic Implications 25%
• Mammalian Target of Rapamycin Signaling Pathway 25%
• Prognostic Model 25%
• Clinical Recurrence 25%
• Clinical Death 25%
• Seminal Vesicle Invasion 25%
• P53 Antigen 25%
• Gleason Sum 25%
• S6 Ribosomal Protein 25%
• Prospective multicenter Trial 25%
• Clinical Covariates 25%

Medicine and Dentistry

• Prostate Cancer 100%
• Prostatectomy 100%
• Progression Free Survival 100%
• Docetaxel 100%
• Protein P53 75%
• Primary Tumor 50%
• Prostate Specific Antigen 50%
• Prognostic Factor 25%
• Recurrent Disease 25%
• Clinical Stage 25%
• Proportional Hazards Model 25%
• Univariate Analysis 25%
• Gleason Score 25%
• Clinical Trial Design 25%
• Post-Hoc Analysis 25%
• Protein Depletion 25%
• Tumor Protein 25%
• Mechanistic Target of Rapamycin 25%
• Protein S6 25%
• Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase 25%
• Protein Kinase B 25%
• Antigen 25%
• Tumor Suppressor Protein 25%
• Seminal Vesicle 25%
• Prognostic Model 25%